Merck KGaA-Product Pipeline Review-2015

Merck KGaA-Product Pipeline Review-2015

  • Products Id :- GMDHC07255CDB
  • |
  • Pages: 112
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Merck KGaA-Product Pipeline Review-2015


Global Markets Direct's, 'Merck KGaA-Product Pipeline Review-2015', provides an overview of the Merck KGaA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Merck KGaA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Merck KGaA including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Merck KGaA's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Merck KGaA's pipeline products

Reasons To Buy

Evaluate Merck KGaA's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Merck KGaA in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Merck KGaA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Merck KGaA and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Merck KGaA

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Merck KGaA and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 7

Merck KGaA Snapshot 8

Merck KGaA Overview 8

Key Information 8

Key Facts 8

Merck KGaA-Research and Development Overview 9

Key Therapeutic Areas 9

Merck KGaA-Pipeline Review 13

Pipeline Products by Stage of Development 13

Pipeline Products-Monotherapy 14

Pipeline Products-Combination Treatment Modalities 15

Pipeline Products-Partnered Products 16

Partnered Products/Combination Treatment Modalities 17

Pipeline Products-Out-Licensed Products 18

Out-Licensed Products/Combination Treatment Modalities 19

Merck KGaA-Pipeline Products Glance 20

Merck KGaA-Late Stage Pipeline Products 20

Filing rejected/Withdrawn Products/Combination Treatment Modalities 20

Phase III Products/Combination Treatment Modalities 21

Merck KGaA-Clinical Stage Pipeline Products 22

Phase II Products/Combination Treatment Modalities 22

Phase I Products/Combination Treatment Modalities 23

Merck KGaA-Early Stage Pipeline Products 24

Preclinical Products/Combination Treatment Modalities 24

Discovery Products/Combination Treatment Modalities 25

Merck KGaA-Drug Profiles 26

cetuximab 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

avelumab 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

choriogonadotropin alfa 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

atacicept 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

ATXMS-1467 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

pimasertib hydrochloride 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

pimasertib hydrochloride + voxtalisib 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

sprifermin 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

tecemotide 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

tepotinib 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

BeiGene-290 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

BGB-283 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

DI-B4 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

MSB-0010360N 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

MSB-0010841 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

MSC-2015103B 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

MSC-2363318A 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

MSC-2364447 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

MSC-2490484A 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

ALX-0751 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

AS-605240 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

cilengitide 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

DDD-498 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

rimeporide 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Small Molecule to Inhibit Aurora B Kinase for Cancer 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Vaccine for Cancer-1 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Vaccine for Cancer-2 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Next-Generation Antibody-Drug Conjugates for Cancer 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Small Molecule to Inhibit SYK for Inflammation 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Small Molecule to Inhibit WNT Pathway for Oncology 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

Small Molecules for Multiple Sclerosis 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Small Molecules for Oncology 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Small Molecules to Agonize TNFR for Cancer 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Merck KGaA-Pipeline Analysis 74

Merck KGaA-Pipeline Products by Target 74

Merck KGaA-Pipeline Products by Route of Administration 77

Merck KGaA-Pipeline Products by Molecule Type 78

Merck KGaA-Pipeline Products by Mechanism of Action 79

Merck KGaA-Recent Pipeline Updates 81

Merck KGaA-Dormant Projects 89

Merck KGaA-Discontinued Pipeline Products 91

Discontinued Pipeline Product Profiles 91

abituzumab 91

anastrozole 91

atacicept 92

cilengitide 92

cladribine 92

Drug to Antagonize Oxytocin Receptor for Pre-term Labor 92

EMD-1204831 92

emfilermin 92

EML-4156 92

matuzumab 92

MSB-0010445 93

MSB-0010841 93

onercept 93

Osteopontin 93

pimasertib hydrochloride 93

plovamer acetate 93

sarizotan hydrochloride 93

tecemotide 93

tucotuzumab celmoleukin 94

Merck KGaA-Company Statement 95

Merck KGaA-Locations And Subsidiaries 97

Head Office 97

Other Locations & Subsidiaries 97

Appendix 111

Methodology 111

Coverage 111

Secondary Research 111

Primary Research 111

Expert Panel Validation 111

Contact Us 111

Disclaimer 112

List of Tables

Merck KGaA, Key Information 8

Merck KGaA, Key Facts 8

Merck KGaA-Pipeline by Indication, 2015 10

Merck KGaA-Pipeline by Stage of Development, 2015 13

Merck KGaA-Monotherapy Products in Pipeline, 2015 14

Merck KGaA-Combination Treatment Modalities in Pipeline, 2015 15

Merck KGaA-Partnered Products in Pipeline, 2015 16

Merck KGaA-Partnered Products/ Combination Treatment Modalities, 2015 17

Merck KGaA-Out-Licensed Products in Pipeline, 2015 18

Merck KGaA-Out-Licensed Products/ Combination Treatment Modalities, 2015 19

Merck KGaA-Filing rejected/Withdrawn, 2015 20

Merck KGaA-Phase III, 2015 21

Merck KGaA-Phase II, 2015 22

Merck KGaA-Phase I, 2015 23

Merck KGaA-Preclinical, 2015 24

Merck KGaA-Discovery, 2015 25

Merck KGaA-Pipeline by Target, 2015 74

Merck KGaA-Pipeline by Route of Administration, 2015 77

Merck KGaA-Pipeline by Molecule Type, 2015 78

Merck KGaA-Pipeline Products by Mechanism of Action, 2015 79

Merck KGaA-Recent Pipeline Updates, 2015 81

Merck KGaA-Dormant Developmental Projects,2015 89

Merck KGaA-Discontinued Pipeline Products, 2015 91

Merck KGaA, Subsidiaries 97

List of Figures

Merck KGaA-Pipeline by Top 10 Indication, 2015 10

Merck KGaA-Pipeline by Stage of Development, 2015 13

Merck KgaA-Monotherapy Products in Pipeline, 2015 14

Merck KGaA-Combination Treatment Modalities in Pipeline, 2015 15

Merck KGaA-Partnered Products in Pipeline, 2015 16

Merck KGaA-Out-Licensed Products in Pipeline, 2015 18

Merck KGaA-Pipeline by Top 10 Target, 2015 74

Merck KGaA-Pipeline by Top 10 Route of Administration, 2015 77

Merck KGaA-Pipeline by Top 10 Molecule Type, 2015 78

Merck KGaA-Pipeline Products by Top 10 Mechanism of Action, 2015 79

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Merck KGaA; Merck KGaA - Key Therapeutics; Merck KGaA - Pipeline Overview and Promising Molecules; Merck KGaA - News; Merck KGaA - Latest Updates; Merck KGaA - Pipeline; Merck KGaA - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102105
Site License
USD 3000 INR 204210
Corporate User License
USD 4500 INR 306315



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]